Harmony Biosciences Holdings (HRMY) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is HRMY's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Harmony Biosciences' Q3 earnings missed estimates as higher costs weighed on profits, while Wakix demand and pipeline progress supported its 2026 revenue outlook.…

Harmony Biosciences Holdings, Inc. (HRMY) Q3 2026 Earnings Call Transcript…

Harmony Biosciences NASDAQ: HRMY reported third-quarter net revenue of $269 million, up from $239 million a year earlier, as demand for its narcolepsy treatment WAKIX continued to grow. The company reiterated its full-ye…

Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.81 per share, missing the Zacks Consensus Estimate of $1 per share. This compares to earnings of $0.87 per share a year ago.…

WAKIX ® Net Revenue in Q3 of $269 Million; Driven by Strong Demand with 400 Net Patient Adds in the Quarter; Reiterates Full Year Guidance of $1.0B to $1.04B…

Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and argenex SE (ARGX). But which of these two stocks offers value investors a better ban…

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and …

Technical indicators have turned bullish for the Barron's Investor Circle stock picks.…

Harmony Biosciences is rated Buy with a 12-month price target of $43, reflecting strong cash generation and WAKIX growth. HRMY's valuation is supported by WAKIX's robust performance, cash reserves, and limited downside i…

PLYMOUTH MEETING, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report third quarter 2026 financial results on Wednesday, November 4, 2026, before t…

Harmony Biosciences (NASDAQ: HRMY - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at Needham and Company LLC in a research note issued on Monday, Benzinga reports. They presently have a $50.00 pric…

Harmony Biosciences gains 27.6% in six months as Wakix sales surge and pipeline advances, with new formulations and clinical milestones offering further growth opportunities.…

Investors weren't cheered by a major change in the company's leadership.…

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY - Get Free Report) gapped down prior to trading on Monday. The stock had previously closed at $40.28, but opened at $38.34. Harmony Biosciences shares last traded at $38.6…

Harmony Biosciences (NASDAQ: HRMY - Get Free Report) and PainReform (NASDAQ: PRFX - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the s…

Harmony Biosciences stock took a tumble Monday after its announced the transition of current CEO Jeffrey Dayno at the end of the year.…

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more attractive …

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and …

PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 trials of HBS-301, i…

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY - Get Free Report) insider Kumar Budur sold 800 shares of the firm's stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $43…

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY - Get Free Report) insider Kumar Budur sold 1,800 shares of the business's stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $…

Harmony Biosciences (NASDAQ: HRMY - Get Free Report) and Sonoma Pharmaceuticals (NASDAQ: SNOA - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based o…

Harmony Biosciences (HRMY) reported earnings 30 days ago. What's next for the stock?…

PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company's investigation of EPX-100 (clemizole hydrochl…

PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Hea…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

